5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Lipid Lowering Therapy
Lipid Lowering Therapy, a crucial component in cardiovascular health, focuses on managing and reducing elevated levels of cholesterol and triglycerides in the bloodstream. This therapeutic approach plays a pivotal role in preventing and mitigating cardiovascular diseases, such as heart attacks and strokes. Often involving medications known as statins, fibrates, or cholesterol absorption inhibitors, Lipid Lowering Therapy aims to regulate lipid levels and promote overall cardiovascular well-being. Alongside lifestyle modifications such as a heart-healthy diet and regular exercise, this therapeutic strategy is instrumental in addressing one of the primary risk factors for cardiovascular complications. Regular monitoring and personalized treatment plans contribute to the effectiveness of Lipid Lowering Therapy, underscoring its significance in the comprehensive management of cardiovascular health.
John R Doty
Intermountain Medical Center, United States
Agustin Joison
Cordoba Catholic University, Argentina
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Bijoy Krishna Banik
National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, IndiaSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Antidiabetic agents – From treating diabetes to providing positive cardiovascular outcome
Syed Raza, Awali Hospital, Bahrain